ConductScience.org, home
Genes
API referenceFor AI assistants

Gene · 28402

IGHV3-69-1: immunoglobulin heavy variable 3-69-1 (pseudogene)

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. IGHV3-69-1: immunoglobulin heavy variable 3-69-1 (pseudogene). Genes, record 28402. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/28402

On this page

Gene

Symbol
IGHV3-69-1
HGNC
Name
immunoglobulin heavy variable 3-69-1 (pseudogene)
HGNC
NCBI Gene ID
28402
NCBI Gene
HGNC ID
HGNC:5631
HGNC
Ensembl
ENSG00000282600
NCBI Gene
Aliases
IGHV3-H, IGHV3-h, IGHV3H
NCBI Gene
Type
pseudo
NCBI Gene

Proteins0

Reviewed human proteins whose Swiss-Prot entry states the gene.

None in this release.

Patents0

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

None in this release.

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,115

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleIGHV3-69-1 papersNewest fiscal year
P30CA016672Cancer Center Support Grant1112025
P30CA008748Cancer Center Support Grant422025
P30CA016058Cancer Center Support Grant382025
ZIAHL002346Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy372025
P30CA015083Mayo Clinic Comprehensive Cancer Center Support Grant192025
P01CA206978Comprehensive dissection of the CLL genome & phenome to improve patient outcomes152025
R01CA177292Targeted Therapies for Lymphoid Malignancies152025
K12CA133250OSU K12 Training Grant in Oncology132025
R01CA155010Personal tumor neoantigens for immunity against chronic lymphocytic leukemia112025
U10CA180820ECOG-ACRIN Network Group Operations Center92025

1 to 10 of 1,115Source NIH's project files

See all 1,115 nih grants

Papers3,091

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.Leukemia202642827117PubTator, text miningPubMed
Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia.Leuk Lymphoma202642822838PubTator, text miningPubMed
Acquired Amegakaryocytic Thrombocytopenia Presenting as Pancytopenia in a Patient With Chronic Lymphocytic Leukemia: A Case Report.Case Rep Hematol202642761550PubTator, text miningPubMed
A specific molecular profiling of secreted rheumatoid factors in Sjögren's disease patients with lymphoma.Rheumatology (Oxford)202642750166PubTator, text miningPubMed
RNA sequencing detects more challenging cases of somatic hypermutation in the IgHV gene in patients with chronic lymphocytic leukemia.Turk J Med Sci202642677266PubTator, text miningPubMed
Consensus-based ranking of determinants for frontline therapy selection in chronic lymphocytic leukemia: A conjoint analysis.Crit Rev Oncol Hematol202642633864PubTator, text miningPubMed
Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).J Natl Cancer Cent202642630801PubTator, text miningPubMed
Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.Hematol Oncol202642607055PubTator, text miningPubMed
Dysregulated BCR repertoire and metabolic state of HBsAg-specific B cells in chronic hepatitis B revealed by integrated single-cell analysis.Hepatol Commun202642579769PubTator, text miningPubMed
Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice.Front Oncol202642528663PubTator, text miningPubMed

1 to 10 of 3,091

See all 3,091 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/28402

GET https://conductscience.org/api/genes/v1/28402/grants?page=2

API referenceFor AI assistants